Jing Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jing Zhou has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
Hailan Xiong
Department of Cardiology, Jiujiang City Key Laboratoryof Cell Therapy, JiuJiang NO.1 People’s Hospital, Jiujiang, China
2 shared publicationsYushan Lei
Department of Endocrinology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China
2 shared publicationsBo Liu
The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China
1 shared publicationChengdi Yuan
Department of Critical Care Medicine, Shenshan Medical Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Shanwei, China
1 shared publication- Chulin Huang
Department of Endocrinology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, 107 Yanjiang West Road, Guangzhou 510120, China
1 shared publication - Diaozhu Lin
Department of Endocrinology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, 107 Yanjiang West Road, Guangzhou 510120, China
1 shared publication
Latest Publications
- Open Access
- 16 October 2026
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 25 (1)
Associations of baseline levels, cumulative exposure, and two-wave patterns of the combined triglyceride-glucose index and frailty index with progression from cardiovascular-kidney-metabolic syndrome stages 0–2 to stages 3–4 and stage 4: a prospective cohort study from CHARLS
- 16 October 2026
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 25 (1)
Open AccessAssociations of baseline levels, cumulative exposure, and two-wave patterns of the combined triglyceride-glucose index and frailty index with progression from cardiovascular-kidney-metabolic syndrome stages 0–2 to stages 3–4 and stage 4: a prospective cohort study from CHARLS
- Open Access
- 22 September 2026
- Published by Springer Nature in Cardiovascular Diabetology
Triglyceride glucose‑derived indices combined with high‑sensitivity C‑reactive protein for predicting glycemic progression and regression in prediabetes: findings from a prospective national cohort study based on baseline and cumulative change analyses
- 22 September 2026
- Published by Springer Nature in Cardiovascular Diabetology
Open AccessTriglyceride glucose‑derived indices combined with high‑sensitivity C‑reactive protein for predicting glycemic progression and regression in prediabetes: findings from a prospective national cohort study based on baseline and cumulative change analyses
- Open Access
- 6 September 2026
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 25 (1)
Joint association of five insulin resistance indices and frailty index with incident cardiometabolic multimorbidity in individuals with cardiovascular–kidney–metabolic syndrome stages 0–3: a prospective cohort study
- 6 September 2026
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 25 (1)
Open AccessJoint association of five insulin resistance indices and frailty index with incident cardiometabolic multimorbidity in individuals with cardiovascular–kidney–metabolic syndrome stages 0–3: a prospective cohort study
- Open Access
- 14 July 2023
- Published by MDPI AG in Metabolites
- Vol. 13 (7) , 850
Fatty Liver Index and Its Association with 10-Year Atherosclerotic Cardiovascular Disease Risk: Insights from a Population-Based Cross-Sectional Study in China
This cross-sectional study aimed to investigate the association between non-alcoholic fatty liver disease (NAFLD) and atherosclerotic cardiovascular disease (ASCVD), a global public health concern. A total of 9044 out of 10,104 adults from Guangzhou, China, were included in the analysis. We utilized the fatty liver index (FLI), a noninvasive indicator of NAFLD, and the pooled cohort equations (PCE) based on the 2013 ACC/AHA Guideline, the China-PAR model, and the Framingham Risk Score to assess the 10-year ASCVD risk. The results demonstrated a significant association between FLI and 10-year ASCVD risk (p < 0.001). Adjusted for age, individuals with high FLI (≥60) had an odds ratio of 3.91 (95% CI 2.52–6.08) compared to those with low FLI (<30). These findings persisted after adjusting for metabolic indicators. Notably, this association was consistently observed across all three risk prediction models: the PCE model, the China-PAR model, and the Framingham Risk Score. In conclusion, our study provides evidence supporting FLI as a reliable indicator of increased 10-year ASCVD risk in Chinese NAFLD patients. FLI serves as a valuable marker for early detection of ASCVD, highlighting its potential in clinical practice for risk assessment and prevention strategies.
- 14 July 2023
- Published by MDPI AG in Metabolites
- Vol. 13 (7) , 850
Open AccessFatty Liver Index and Its Association with 10-Year Atherosclerotic Cardiovascular Disease Risk: Insights from a Population-Based Cross-Sectional Study in China
This cross-sectional study aimed to investigate the association between non-alcoholic fatty liver disease (NAFLD) and atherosclerotic cardiovascular disease (ASCVD), a global public health concern. A total of 9044 out of 10,104 adults from Guangzhou, China, were included in the analysis. We utilized the fatty liver index (FLI), a noninvasive indicator of NAFLD, and the pooled cohort equations (PCE) based on the 2013 ACC/AHA Guideline, the China-PAR model, and the Framingham Risk Score to assess the 10-year ASCVD risk. The results demonstrated a significant association between FLI and 10-year ASCVD risk (p < 0.001). Adjusted for age, individuals with high FLI (≥60) had an odds ratio of 3.91 (95% CI 2.52–6.08) compared to those with low FLI (<30). These findings persisted after adjusting for metabolic indicators. Notably, this association was consistently observed across all three risk prediction models: the PCE model, the China-PAR model, and the Framingham Risk Score. In conclusion, our study provides evidence supporting FLI as a reliable indicator of increased 10-year ASCVD risk in Chinese NAFLD patients. FLI serves as a valuable marker for early detection of ASCVD, highlighting its potential in clinical practice for risk assessment and prevention strategies.